The global cardiovascular diagnostics devices market size was valued at USD 25.26 billion in 2025 and is projected to grow from USD 26.63 billion in 2026 to USD 40.62 billion by 2034, registering a CAGR of 5.42% during the forecast period (2026-2034). North America dominated the cardiovascular diagnostics devices market with a share of 38.85% in 2025.
Cardiovascular diagnostic devices are medical instruments and systems used to detect abnormalities in heart function, assess blood circulation, and identify cardiovascular conditions before they lead to serious complications. ardiovascular diagnostic devices are commonly classified under HSN Code 9018 (instruments and appliances used in medical, surgical, dental, or veterinary sciences) and SIC Code 3845 (Electromedical and Electrotherapeutic Apparatus).
The cardiovascular diagnostics devices market demand is driven by the burden of heart disease, the need for early diagnosis, and the use of noninvasive cardiac testing. Healthcare providers are increasingly using ECG systems, echocardiography equipment, cardiac CT and MRI systems, Holter monitors, and stress testing devices.
Download a Free Sample To learn more about this report,
Integration of Cardiovascular Diagnostics with Electronic Health Records
The cardiovascular diagnostics market analysis shows a shift towards the integration of cardiovascular diagnostics with electronic health records to connect diagnostic results with patient medical histories and clinical information. This integration is improving clinical data availability and enabling healthcare providers to make more informed treatment decisions.
Adoption of Personalized Cardiovascular Risk Assessment
Cardiovascular diagnostics market is witnessing growth in personalized cardiovascular risk assessment as healthcare providers increasingly use individual patient data to identify the likelihood of cardiovascular conditions. Diagnostic information, medical history, lifestyle factors, cardiac biomarkers, and patient-specific characteristics can be combined to develop more individualized risk profiles.
Supply chain disruptions are expected to have a high impact on the cardiovascular diagnostics market share due to dependence on semiconductors and medical device manufacturing networks. The market is expected to follow a stair-step recovery, as shortages of diagnostic components, reagent supply constraints, and transportation disruptions can affect device production and diagnostic service availability in phases before component supplies and manufacturing capacity stabilize. The market is expected to grow at a CAGR of 5.42%, but supply chain constraints could approximately lower this by 0.8 percentage points, resulting in short-term growth of around 4.62%. As supply conditions normalize, the cardiovascular diagnostics market growth is expected to gradually return to 5.42%.
The cardiovascular diagnostics market forecasts strategic investment activity driven by AI-powered cardiovascular imaging andremote patient monitoring.
Key Investment and Funding Activities in Cardiovascular Diagnostics Market, 2026
Elucid
USD 55 Million
In September 2026, Elucid raised USD 55 million in Series D funding to accelerate commercialization of its AI-powered cardiovascular imaging platform and expand partnerships with medical technology companies.
Implicity
USD 40 Million
In September 2026, Implicity secured USD 40 million in growth equity funding to expand its AI-powered cardiac monitoring platform in the United States, strengthen its European presence, and accelerate AI development for cardiac data analysis.
Demand for Portable Cardiovascular Diagnostic Devices and Need for Continuous Heart Monitoring Drives Market
Demand for portable cardiovascular diagnostic devices is growing as healthcare providers seek convenient ways to monitor heart health. Portable devices allow testing and monitoring outside traditional hospital settings and can support quicker access to patient data. Their use in clinics, home care, and remote monitoring is supporting market growth.
The need for continuous heart monitoring is driving demand for cardiovascular diagnostic solutions that can track heart activity over longer periods. Continuous monitoring can help identify irregular heart rhythms and other changes that may not appear during a short clinical test.
Risk of False Positive or False Negative Results and High Cost of Advanced Devices Restrain Market Expansion
Risk of false positive or false negative results can limit confidence in cardiovascular diagnostic technologies. Incorrect results may lead to unnecessary follow up testing or delayed identification of cardiovascular conditions, increasing the burden on healthcare providers and patients. These concerns can make healthcare professionals more cautious about relying on certain diagnostic solutions and may restrain market growth.
High cost of advanced cardiovascular diagnostic devices can limit their adoption, particularly among smaller hospitals and healthcare facilities with restricted budgets. Advanced imaging systems, monitoring devices, wearable diagnostics, and other specialized equipment may require substantial investment in addition to installation, maintenance, and staff training costs.
Expansion of Cardiovascular Diagnostics in Preventive Health Checkups and Cardiac Rehabilitation Offers Growth Opportunities
Focus on preventive healthcare is creating opportunities for cardiovascular diagnostic providers to serve hospitals, diagnostic centers, corporate health programs, and wellness clinics. Revenue can be generated through diagnostic packages, screening programs, laboratory services, and institutional contracts, contributing to cardiovascular diagnostics market growth.
The need for structured recovery after cardiac procedures is creating opportunities for diagnostic providers to serve hospitals, rehabilitation centers, and cardiac care clinics. Diagnostic assessments can support evaluation of patient recovery, exercise readiness, and treatment effectiveness during rehabilitation programs. Revenue can be generated through diagnostic services, rehabilitation packages, testing programs, and long-term healthcare contracts.
Imaging system dominated the product segment in 2025, accounting for a share of 25.84% in 2025, owing to its extensive use in detecting and evaluating structural and functional abnormalities of the heart and blood vessels.
The cardiac MRI segment is expected to achieve a growth rate of 6.61% during the forecast period, supported by its high resolution imaging capabilities and increasing use for detailed assessment of cardiac structure, tissue characteristics, and function.
Request Customizationto receive a tailored report.
Analyzers accounted for a share of 30.84% in 2025, reflecting their widespread use for rapid cardiovascular-related testing and efficient processing of diagnostic samples.
The high-sensitivity CRP kits segment is anticipated to record a CAGR of 6.17% during the forecast period, driven by increasing demand for sensitive inflammatory marker testing to support cardiovascular risk assessment.
Coronary artery disease dominated the disease segment with a share of 24.56% in 2025, owing to the high prevalence of coronary conditions and the growing need for timely diagnosis and monitoring.
The heart failure segment is projected to undergo growth at a CAGR of 6.21% during the forecast period, fueled by the increasing burden of heart failure and demand for accurate diagnostic and monitoring solutions.
Hospitals dominated the end-use segment with a share of 46.38% in 2025, reflecting the availability of advanced diagnostic infrastructure, specialized cardiology diagnostic departments, and comprehensive cardiovascular care services.
The ambulatory surgical centers segment is likely to witness a CAGR of 6.37% during the forecast period, supported by growing preference for outpatient cardiac procedures, shorter hospital stays, and cost-efficient healthcare delivery.
Speak to an Analystto discuss market opportunities.
The North America cardiovascular diagnostics market accounted for a share of 38.85% in 2025.
The U.S. market benefits from the American Heart Association’s Life’s Essential 8 framework, which emphasizes regular monitoring of cardiovascular health and risk factors. This focus is supporting greater use of ECG and echocardiography in cardiovascular assessment, particularly for patients requiring evaluation of heart rhythm and structural abnormalities.
Canada’s cardiovascular care ecosystem is supported by Heart & Stroke’s cardiovascular health initiatives, which promote early identification and management of cardiovascular risk. Increasing attention to early diagnosis is supporting the use of ECG and echocardiography across hospitals, diagnostic centers, and outpatient cardiac care settings.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cardiovascular diagnostics market is expected to grow at a CAGR of 7.39% during the forecast period, making it the fastest-growing region.
China’s Healthy China 2030 initiative emphasizes prevention, early detection, and management of major chronic diseases, including cardiovascular conditions. This focus is strengthening the need for cardiac imaging and stress testing to identify cardiovascular abnormalities and assess patients at risk of coronary artery disease.
Japan’s Health Japan 21 (Third Term) promotes prevention of lifestyle-related diseases and improved management of cardiovascular risk factors. Greater emphasis on early cardiovascular assessment is supporting the use of cardiac imaging and diagnostic stress testing for patients with suspected heart disease.
India’s National Programme for Prevention and Control of Non Communicable Diseases (NP-NCD) focuses on screening and early management of cardiovascular diseases and other major non-communicable diseases. Expanded screening activity is increasing demand for diagnostic approaches that support coronary artery disease detection and cardiovascular risk assessment.
The Europe cardiovascular diagnostics market is projected to grow at a CAGR of 4.76% during the forecast period.
Germany’s Disease Management Program for Coronary Heart Disease (DMP KHK) supports structured diagnosis, monitoring, and long term management of patients with coronary heart disease. This is supporting demand for cardiac monitoring to track disease progression and treatment outcomes.
UK’s NHS Health Check programme supports cardiovascular risk assessment and early identification of cardiovascular conditions among eligible adults. This focus is supporting demand for heart disease diagnosis through routine cardiovascular risk assessment and diagnostic testing.
The Latin America cardiovascular diagnostics market is estimated to register a growth rate of 5.63% during the forecast period. Brazil’s Strategic Action Plan for Tackling Chronic Noncommunicable Diseases emphasizes prevention, risk assessment, and early detection of cardiovascular conditions.
Mexico’s National Strategy for the Prevention and Control of Overweight, Obesity and Diabetes promotes early identification of chronic disease risk factors and stronger preventive healthcare. The emphasis on cardiovascular assessment also supports the adoption of computed tomography (CT) for detailed evaluation of coronary and cardiovascular abnormalities.
Middle East & Africa's cardiovascular diagnostics market is expected to experience a growth rate of CAGR of 5.89% during the forecast period. UAE’s National Strategy for Wellbeing 2031 promotes preventive healthcare and improved quality of life, supporting greater attention to early detection and management of chronic diseases. This encourages the adoption of magnetic resonance imaging (MRI) for detailed cardiovascular assessment and evaluation of structural abnormalities.
South Africa’s National Strategic Plan for the Prevention and Control of Non-Communicable Diseases 2022–2027 emphasizes stronger screening, diagnosis, and management of cardiovascular conditions, supporting demand for diagnostic devices.
The cardiovascular diagnostics market competitive landscape is highly fragmented, with established diagnostic technology providers, cardiovascular equipment companies, and medical imaging solution providers. Key players such as Medtronic plc, Boston Scientific Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, and GE HealthCare Technologies Inc. are estimated to account for approximately 30–35% of the global cardiovascular diagnostics market share.
Established players compete mainly through cardiac imaging technologies, diagnostic testing systems, cardiovascular biomarker testing, electrocardiography solutions, diagnostic accuracy, and clinical research capabilities. Emerging and regional players in the cardiovascular diagnostics market ecosystem focus on specialized diagnostic tools, cost-effective testing solutions, and portable diagnostic devices.
August 2026: GE HealthCare introduced three Vivid cardiovascular ultrasound systems Explorer, Advanced, and Focus.
April 2026: Abbott received FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography platform that analyzes coronary plaque and supports stent sizing and placement during coronary interventions.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Cranial And Facial Implants Market Size, Forecast, Demand, Opportunities, 2034
Arthroscopy Devices Market Size, Forecast, Opportunities, 2034
Ablation Devices Market Size, Forecast, Demand, Opportunities, 2034
Coronary Guidewires Market Size, Forecast, Demand, Opportunities, 2034
Coagulation Analyzers Market Size, Forecast, Demand, Opportunities, 2034
Centesis Catheters Market Size, Forecast, Opportunities, 2034
We are featured on:
sales@straitsresearch.com